Omidon 60ml Suspension

Omidon Oral Suspension 5 mg/5 ml

Generic: Domperidone Maleate 5 mg/5 ml
Manufacturer: Incepta Pharmaceuticals Ltd.
Dosage Form: Oral Suspension
Pack Size: 60 ml bottle

Indications

Omidon Suspension is indicated for:

• Dyspeptic symptom complex associated with delayed gastric emptying, gastroesophageal reflux and oesophagitis: epigastric fullness, abdominal distension, upper abdominal pain, eructation, flatulence, early satiety, nausea, vomiting, heartburn, and regurgitation
• Non-ulcer dyspepsia
• Acute nausea and vomiting of functional, organic, infectious, or dietary origin; nausea induced by radiotherapy, drug therapy, or migraine
• Parkinson's disease: nausea and vomiting induced by dopamine agonist therapy (e.g., bromocriptine, L-dopa)
• Speeding barium transit in follow-through radiological studies

Pharmacology

Domperidone is a peripheral dopamine (D2) receptor antagonist that acts principally by blocking dopamine receptors in the Chemoreceptor Trigger Zone (CTZ) located outside the blood-brain barrier, producing a central antiemetic effect without significant psychotropic or neurological side effects.

Its gastroprokinetic action results from blockade of inhibitory dopamine receptors in the gastric wall and upper gastrointestinal tract. This restores normal gastrointestinal motility and tone, facilitates gastric emptying, enhances antral and duodenal peristalsis, and regulates pyloric contraction. Domperidone also increases oesophageal peristalsis and lower oesophageal sphincter pressure, thereby preventing regurgitation of gastric contents. Because domperidone has poor penetration through the blood-brain barrier in adults, extrapyramidal side effects are rare.

Dosage & Administration

Administer 15–30 minutes before meals and, if necessary, before retiring.

Shake the bottle well before use.

Contraindications

• Known hypersensitivity to domperidone or any component of the formulation
• Neonates (immature blood-brain barrier increases risk of neurological effects)
• Gastrointestinal haemorrhage, mechanical obstruction, or perforation (where stimulation is contraindicated)
• Prolactin-releasing pituitary tumour (prolactinoma)

Warnings & Precautions

• Children: Use with absolute caution — incompletely developed blood-brain barrier increases risk of extrapyramidal reactions.
• Hepatic impairment: Domperidone is highly metabolised in the liver; use with caution and consider dose reduction.
• Renal impairment: In severe renal insufficiency, the elimination half-life is prolonged (7.4 → 20.8 hours). Reduce dosing frequency to once or twice daily on repeated administration.
• CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, HIV protease inhibitors) may increase domperidone plasma levels — use with caution.
• Anticholinergic drugs may antagonise the antidyspeptic effect of domperidone.

Side Effects

• Rare: Transient intestinal cramps
• Extrapyramidal reactions: Rare in adults, slightly more common in young children; resolve spontaneously on discontinuation
• Endocrine: Hyperprolactinaemia (rare) — may cause galactorrhoea and gynaecomastia
• Allergic: Skin rash, urticaria (rare)

Drug Interactions

• Antacids / antisecretory drugs: Reduce oral bioavailability of domperidone — do not administer simultaneously
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): May increase domperidone plasma concentrations
• Anticholinergics: May antagonise prokinetic effect
• Dopaminergic agonists (bromocriptine, L-dopa): Domperidone suppresses their peripheral GI side effects without affecting central action

Pregnancy & Lactation

Animal studies at doses up to 160 mg/kg/day showed no teratogenic effects. In humans, no increased risk of malformations has been reported. Use during the first trimester only if justified by therapeutic benefit. Domperidone is excreted in breast milk at concentrations ~4× lower than maternal plasma; breastfeeding is not recommended unless the expected benefit outweighs potential risk.

Overdose

Symptoms may include drowsiness, disorientation, and extrapyramidal reactions (especially in children). Management: activated charcoal, close observation. Anticholinergic or antihistamine drugs with anticholinergic properties may help control extrapyramidal reactions.

Storage

Store below 30°C, protected from light and moisture. Keep out of reach of children.

Disclaimer: This product information is for reference purposes only and does not substitute professional medical advice, diagnosis, or treatment. Always consult a registered physician or qualified healthcare professional before taking any medication.